Format

Send to

Choose Destination
Int J Cancer. 2016 Feb 15;138(4):881-90. doi: 10.1002/ijc.29825. Epub 2015 Sep 8.

The distribution of BRAF gene fusions in solid tumors and response to targeted therapy.

Author information

1
Foundation Medicine, Inc., Cambridge, MA.
2
Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, NY.
3
Keck School of Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA.

Abstract

Although the BRAF V600E base substitution is an approved target for the BRAF inhibitors in melanoma, BRAF gene fusions have not been investigated as anticancer drug targets. In our study, a wide variety of tumors underwent comprehensive genomic profiling for hundreds of known cancer genes using the FoundationOne™ or FoundationOne Heme™ comprehensive genomic profiling assays. BRAF fusions involving the intact in-frame BRAF kinase domain were observed in 55 (0.3%) of 20,573 tumors, across 12 distinct tumor types, including 20 novel BRAF fusions. These comprised 29 unique 5' fusion partners, of which 31% (9) were known and 69% (20) were novel. BRAF fusions included 3% (14/531) of melanomas; 2% (15/701) of gliomas; 1.0% (3/294) of thyroid cancers; 0.3% (3/1,062) pancreatic carcinomas; 0.2% (8/4,013) nonsmall-cell lung cancers and 0.2% (4/2,154) of colorectal cancers, and were enriched in pilocytic (30%) vs. nonpilocytic gliomas (1%; p < 0.0001), Spitzoid (75%) vs. nonSpitzoid melanomas (1%; p = 0.0001), acinar (67%) vs. nonacinar pancreatic cancers (<1%; p < 0.0001) and papillary (3%) vs. nonpapillary thyroid cancers (0%; p < 0.03). Clinical responses to trametinib and sorafenib are presented. In conclusion, BRAF fusions are rare driver alterations in a wide variety of malignant neoplasms, but enriched in Spitzoid melanoma, pilocytic astrocytomas, pancreatic acinar and papillary thyroid cancers.

KEYWORDS:

BRAF fusions; NGS; Sptizoid melanoma; cancer; comprehensive genomic profiling; pancreatic acinar carcinoma; pilocytic astrocytoma; solid tumors; targeted therapy

PMID:
26314551
PMCID:
PMC5049644
DOI:
10.1002/ijc.29825
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center